EUVIMEDEUVIMED entdecken
Crossref

Real-World Implementation of a Genotype-Guided P2Y12 Inhibitor De-Escalation Strategy in Acute Coronary Syndrome Patients

Jaouad Azzahhafi, Wout W A van den Broek, Dean R P P Chan Pin Yin, Niels M R van der Sangen, Shabiga Sivanesan, Salahodin Bofarid, Joyce Peper, Daniel M F Claassens, Paul W A Janssen, Ankie M Harmsze, Ronald J Walhout, Melvyn Tjon Joe Gin und 9 weitere

JACC: Cardiovascular Interventions · 2024-09 · 17 (17) · 1996-2007

DOI: 10.1016/j.jcin.2024.06.020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Cardiovascular Interventions, 2024-09. Verfasst von Jaouad Azzahhafi und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands. Electronic address: j.azzahhafi@antoniusziekenhuis.nl. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: CYP2C19 genotype-guided de-escalation from ticagrelor or prasugrel to clopidogrel may optimize the balance between ischemic and bleeding risk in patients with acute coronary syndrome (ACS). OBJECTIVES: This study sought to compare bleeding and ischemic event rates in genotyped patients vs standard care. METHODS: Since 2015, ACS patients in the multicenter FORCE-ACS (Future Optimal Research and Care Evaluation in Patients with Acute Coronary Syndrome) registry received standard dual antiplatelet therapy (DAPT). Since 2021, genotype-guided P2Y12 inhibitor de-escalation was recommended at a single center, switching noncarriers of the loss-of-function allele CYP2C19∗3 or CYP2C19∗2 from ticagrelor or prasugrel to clopidogrel, whereas loss-of-function carriers remained on ticagrelor or prasugrel. The primary ischemic endpoint, a composite of cardiovascular mortality, myocardial infarction, or stroke, and the primary bleeding endpoint, Bleeding Academic Research Consortium 2, 3, or 5 bleeding, were compared between a genotyped cohort and a cohort treated with standard DAPT after 1 year. RESULTS: Among 5,321 enrolled ACS patients, 406 underwent genotyping compared with 4,915 nongenotyped ACS patients on standard DAPT. In the genotyped cohort, 65.3% (n = 265) were noncarriers, 88.7% (n = 235) of whom were switched to clopidogrel. The primary ischemic endpoint occurred in 5.2% (n = 21) of patients in the genotyped cohort compared to 6.9% (n = 337) in the standard care cohort (adjusted HR: 0.82; 95% CI: 0.53-1.28). The primary bleeding rate was significantly lower in the genotyped cohort compared to the standard care cohort (4.7% vs 9.8%; adjusted HR: 0.47; 95% CI: 0.30-0.76). CONCLUSIONS: The implementation of a CYP2C19 genotype-guided P2Y12 inhibitor de-escalation strategy in a real-world ACS population resulted in lower bleeding rates without an increase in ischemic events compared to a standard DAPT regimen.

Schlagwörter

Stichwörter der Autor:innen

CYP2C19acute coronary syndromedual antiplatelet therapygenotype-guided therapy

Autor:innen und Institutionen

  • Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands. Electronic address: j.azzahhafi@antoniusziekenhuis.nl.
  • Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands.
  • Department of Cardiology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.
  • Department of Cardiology, Isala Hospital, Zwolle, the Netherlands.
  • Department of Cardiology, Haga Hospital, The Hague, the Netherlands.
  • Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein, the Netherlands.

Zitieren

APA

Azzahhafi, J., van den Broek, W. W. A., Chan Pin Yin, D. R. P. P., van der Sangen, N. M. R., Sivanesan, S., Bofarid, S., Peper, J., Claassens, D. M. F., Janssen, P. W. A., Harmsze, A. M., Walhout, R. J., Tjon Joe Gin, M., Nicastia, D. M., Langerveld, J., Vlachojannis, G. J., van Bommel, R. J., Appelman, Y., van Schaik, R. H. N., Henriques, J. P. S., …, & Ten Berg, J. M. (2024). Real-World Implementation of a Genotype-Guided P2Y12 Inhibitor De-Escalation Strategy in Acute Coronary Syndrome Patients. JACC: Cardiovascular Interventions, 17(17), 1996-2007. https://doi.org/10.1016/j.jcin.2024.06.020

Vancouver

Azzahhafi J, van den Broek WWA, Chan Pin Yin DRPP, van der Sangen NMR, Sivanesan S, Bofarid S, et al. Real-World Implementation of a Genotype-Guided P2Y12 Inhibitor De-Escalation Strategy in Acute Coronary Syndrome Patients. JACC: Cardiovascular Interventions. 2024;17(17):1996-2007. doi:10.1016/j.jcin.2024.06.020

BibTeX
@article{Azzahhafi2024,
  author = {Azzahhafi, Jaouad and van den Broek, Wout W A and Chan Pin Yin, Dean R P P and van der Sangen, Niels M R and Sivanesan, Shabiga and Bofarid, Salahodin and Peper, Joyce and Claassens, Daniel M F and Janssen, Paul W A and Harmsze, Ankie M and Walhout, Ronald J and Tjon Joe Gin, Melvyn and Nicastia, Deborah M and Langerveld, Jorina and Vlachojannis, Georgios J and van Bommel, Rutger J and Appelman, Yolande and van Schaik, Ron H N and Henriques, José P S and Kikkert, Wouter J and Ten Berg, Jurriën M},
  title = {Real-World Implementation of a Genotype-Guided P2Y12 Inhibitor De-Escalation Strategy in Acute Coronary Syndrome Patients},
  journal = {JACC: Cardiovascular Interventions},
  year = {2024},
  volume = {17},
  number = {17},
  pages = {1996--2007},
  doi = {10.1016/j.jcin.2024.06.020}
}
Kostenlos starten →